Sign In
Buy AGIO
$30.02
-2.73 (-8.34%)
At Close: Jul 31, 2026
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
01:21pm, Friday, 31'st Jul 2026
Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.
Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript
01:53pm, Thursday, 30'th Jul 2026
Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript
Agios Pharmaceuticals Q2 Earnings Call Highlights
10:06am, Thursday, 30'th Jul 2026
Agios Pharmaceuticals NASDAQ: AGIO reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company c
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
10:00am, Thursday, 30'th Jul 2026
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advise
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
08:51am, Thursday, 30'th Jul 2026
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.86. This compares to a loss of $1.93 per share a year ago.
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
06:30am, Thursday, 30'th Jul 2026
Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 Strong U.S. commercial la
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
05:24pm, Tuesday, 28'th Jul 2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such invest
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
01:41pm, Monday, 27'th Jul 2026
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:01am, Thursday, 23'rd Jul 2026
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
01:26pm, Wednesday, 22'nd Jul 2026
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
11:44am, Tuesday, 21'st Jul 2026
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock is trading lower after the update on the sickle cell disease program.
Agios Pharma to discontinue sickle cell disease treatment development
07:07am, Tuesday, 21'st Jul 2026
Agios Pharmaceuticals said on Tuesday it will stop development of its sickle cell disease treatment, sending its shares down 14% in premarket trading.
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
07:00am, Tuesday, 21'st Jul 2026
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
07:35am, Friday, 10'th Jul 2026
Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition is coming from Novo Nordisk.
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
11:36am, Wednesday, 08'th Jul 2026
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
